Skip to content
SalamTechs
العربيةBusiness services

Nucleai analyses tissue images and related clinical information to support drug development.

Introduce me to Nucleai
Nucleai website sharing image

Image source: company website sharing image

Founders & company facts

Sources reviewed:

Reported cumulative funding

$60,500,000 · Source

This index includes companies with publicly reported total funding up to US$150 million. This is a reported total, not valuation, the latest round size or confirmation of an open round. Funding reviewed: .

Documented founding team

Founded
2018Source
Reported Israeli location
Tel Aviv-YafoSource
Team range in directory
51-200Source
Reported business model
B2BSource

Selected disclosed financing

Selected transactions, with dates, funding types and reported participants.

  1. Apr 2024$14MSeries B
    Named participants

    M Ventures · Debiopharm Innovation Fund · Vertex Ventures Israel · Sanofi Ventures · Grove Ventures · Section 32

    Source
  2. Mar 2022$33MSeries B
    Named participants

    Sanofi Ventures · Vertex Ventures Israel · Fosun RZ Capital · Grove Ventures · Section 32 · Debiopharm Group

    Source

Founding year follows the cited company history (2018); the directory records 2017. Source

Company overview

Product & customers

Nucleai analyses tissue images and related clinical information to support drug development. Its platform combines multimodal tissue analysis with outcome-linked data and expert-led interpretation, helping biopharma teams investigate treatment response and develop biomarker strategies.

Commercial potential · editorial analysis

Understanding which patients may benefit from a therapy can be valuable across multiple drug programmes. The opportunity is a repeat research relationship built on useful biological insight, reliable data processing and integration into development decisions.

What to validate

Review reproducibility across tissue sources, validation cohorts and partner programmes. Data rights, the balance between services and scalable software, and evidence that analyses influence consequential development decisions are important commercial diligence questions.

Explore the company website

Product source reviewed on . Company source